Atherothrombosis

Millions are at Risk

Atherothrombosis is the underlying disease process common to patients with ischemic stroke, heart attack, and peripheral arterial disease (PAD). These patients face an ongoing threat of future atherothrombotic events. 15


Threat of ischemic stroke, heart attack, and Peripheral Arterial Disease (PAD) post stroke (picture)

Ischemic Stroke - 616,000 Per Year 15
From 6 months to 1 year post stroke: the most common cause of death is cardiovascular (CV) disease. 50% of ischemic stroke patients have concomitant atherothrombosis in other vascular beds 18


Myocardial Infarction (MI) - 1.2 Million Per Year 15
Within 1 year: 31% of Acute Coronary Syndrome (ACS) patients experience a recurrent ischemic event. 68% of MIs evolve from plaques that are only mildly to moderately obstructive. 17


PAD – 8 Million 15
Within 3 years of diagnosis: 33% of PAD patients have a CV event. PAD is a coronary heart disease (CHD) risk equivalent. 18


Relevant Studies — The REACH Registry & ACTION Registry®–GWTG™

The REduction of Atherothrombosis for Continued Health — or REACH — Registry conducted a study of more than 69,000 patients, to identify comparable patterns in atherosclerosis risk factor prevalence. Read about the REACH Registry study.

ACTION Registry–GWTG is a national, risk-adjusted, outcomes-based quality improvement program that helps participating facilities measure and improve care for high-risk ACS patients with STEMI and NSTEMI. The ACTION Registry–GWTG is a result of the collaboration between the two leading national coronary artery disease registries, the NCDR® ACTION Registry–GWTG and the American Heart Association (AHA) Get With The GuidelinesSM-CAD Registry.

Combining the strengths of the two programs, ACTION Registry–GWTG will collect a comprehensive set of data elements that provide healthcare professionals and their facilities with the information they need to monitor and improve adherence to the most current, science-based ACC/AHA treatment guidelines. Read more about ACTION Registry–GWTG

Indications
–
Use PLAVIX plus aspirin for patients with non–ST–segment elevation acute coronary syndrome (UA/non–Q–wave MI), including patients to be managed medically and those to be managed with percutaneous coronary intervention (with or without stent) or CABG, to decrease the rate of a combined end point of CV death, MI, or stroke as well as the rate of a combined end point of CV death, MI, stroke, or refractory ischemia.

–
Use PLAVIX plus aspirin for patients with ST–segment elevation acute myocardial infarction to reduce the rate of death from any cause and the rate of a combined end point of death, reinfarction, or stroke. This benefit is not known to pertain to patients who receive primary angioplasty.

–
Use PLAVIX alone for patients with a history of recent stroke, recent MI, or established PAD to reduce the rate of a combined end point of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
Important Risk Information 18
–
PLAVIX is contraindicated in patients with active pathologic bleeding such as peptic ulcer or intracranial hemorrhage. PLAVIX should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or coadministration with NSAIDs or warfarin. (See CONTRAINDICATIONS and PRECAUTIONS.*)

–
The rates of major and minor bleeding were higher in patients treated with PLAVIX plus aspirin compared with placebo
plus aspirin in clinical trials. (See ADVERSE REACTIONS.*)

–
As part of the worldwide post–marketing experience with PLAVIX, there have been cases of reported thrombotic thrombocytopenic purpura (TTP), some with fatal outcome. TTP has been reported rarely following use of PLAVIX, sometimes after a short exposure (<2 weeks). TTP is a serious condition that can be fatal and requires urgent treatment including plasmapheresis (plasma exchange). (See WARNINGS.*)

–
In clinical trials, the most common clinically important side effects were pruritus, purpura, diarrhea, and rash; infrequent events included intracranial hemorrhage (0.4%) and severe neutropenia (0.05%). (See ADVERSE REACTIONS.*)